- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06317662
Testare l'aggiunta del farmaco antitumorale Venetoclax e/o dell'immunoterapia antitumorale Blinatumomab al consueto trattamento chemioterapico per neonati con leucemia KMT2A-riarrangiata o KMT2A-non-riarrangiata di nuova diagnosi
Uno studio di fase 2 su blinatumomab in combinazione con chemioterapia per neonati con leucemia linfoblastica acuta di nuova diagnosi con randomizzazione di pazienti riarrangiati per KMT2A all'aggiunta di Venetoclax
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or without a KMT2A gene rearrangement (KMT2A-germline [G]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax and/or blinatumomab to standard chemotherapy may be more effective at treating patients with ALL than standard chemotherapy alone, but it may also cause more side effects. This clinical trial evaluates the safety and effectiveness of adding venetoclax and/or blinatumomab to chemotherapy for the treatment of infants with KMT2A-R or KMT2A-G ALL.
Panoramica dello studio
Stato
Intervento / Trattamento
- Droga: Cyclophosphamide
- Droga: Doxorubicin
- Droga: Vincristine
- Procedura: Computed Tomography
- Procedura: Magnetic Resonance Imaging
- Procedura: Echocardiography Test
- Procedura: Multigated Acquisition Scan
- Biologico: Blinatumomab
- Procedura: Bone Marrow Aspiration
- Droga: Daunorubicin
- Procedura: Lumbar Puncture
- Droga: Methylprednisolone
- Procedura: Biospecimen Collection
- Droga: Calaspargase Pegol
- Droga: Therapeutic Hydrocortisone
- Droga: Asparaginase Erwinia chrysanthemi
- Droga: Cytarabine
- Droga: Dexamethasone
- Procedura: FDG-Positron Emission Tomography
- Droga: Leucovorin
- Droga: Levoleucovorin
- Droga: Mercaptopurine
- Droga: Methotrexate
- Droga: Thioguanine
- Droga: Venetoclax
- Droga: Prednisolone
- Droga: Prednisone
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability of venetoclax in addition to a standard chemotherapy backbone and two cycles of blinatumomab in infants (aged 365 days or less at diagnosis) with newly diagnosed KMT2A-R ALL.
II. To determine in a randomized manner if the addition of venetoclax to induction chemotherapy improves end of induction minimal residual disease (MRD)-negative remission rates in infants with KMT2A-R ALL.
SECONDARY OBJECTIVES:
I. To estimate the MRD-negative remission rate for all eligible infants with KMT2A-R ALL treated with venetoclax at the recommended phase 2 dose (RP2D).
II. To compare event free survival (EFS) rates of infants with KMT2A-R ALL treated on arm B to those treated on arm A.
III. To compare 3-year EFS rates of infants with KMT2A-R ALL treated on arm A to historical controls.
IV. To determine the feasibility of treating infants with KMT2A-G ALL with a Children's Oncology Group (COG) high risk ALL chemotherapy backbone and two cycles of blinatumomab and estimate the 3-year EFS rate of infants with KMT2A-G ALL treated on arm C.
V. To characterize the pharmacokinetics (PK) of venetoclax in infants.
EXPLORATORY OBJECTIVES:
I. To describe 3-year EFS rate of infants with KMT2A-R ALL treated on arm B. II. To evaluate the use of high-throughput sequencing (HTS) for MRD detection in infant ALL compared to centralized flow cytometry.
III. To characterize the PK of calaspargase pegol in infants with ALL. IV. To report the incidence of CD19 negative relapse and myeloid switch relapse with protocol therapy.
V. To evaluate the impact of venetoclax in combination with chemotherapy on T-cell subsets and function.
VI. To describe the feasibility of T-cell collection and success of T-cell manufacturing for infants with KMT2A-R ALL who receive chimeric antigen receptor (CAR) T- cell therapy after coming off protocol therapy.
VII. To determine predictors of response and resistance to venetoclax and overall protocol therapy.
VIII. To evaluate the impact of subsequent anti-cancer therapy on overall survival after coming off protocol therapy.
IX. To compare overall survival (OS) rates of infants by arms and to historical OS rates.
OUTLINE:
STEROID PREPHASE: All patients receive prednisone or prednisolone orally (PO) or nasogastrically (NG) three times daily (TID) or methylprednisolone intravenously (IV) TID for 7 days prior to the start of induction therapy (on days 1-7).
Patients who are KMT2A gene rearrangement positive are assigned to the safety phase cohort during the safety phase of the study, or randomized between Arm A and Arm B during the expansion phase of the study. Patients who are KMT2A gene rearrangement negative are assigned to Arm C.
SAFETY PHASE COHORT (CLOSED TO ACCRUAL 06/03/2026):
INDUCTION: Patients receive venetoclax PO or NG once daily (QD) on days 1-7, 1-10, or 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy (methotrexate, hydrocortisone, cytarabine) intrathecally (IT) on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when absolute neutrophil counts (ANC) >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-central nervous system (CNS) extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine subcutaneously (SC) QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
EXPANSION PHASE: After completion of Safety phase, patients who are KMT2A gene rearrangement positive are randomized to Arm A or Arm B.
ARM A:
INDUCTION: Patients receive daunorubicin IV over 1-15 minutes on days 1 and 2, cytarabine SC or IV over 1-30 minutes on days 1-14, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29, or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
ARM B: Patients are assigned to 1 of 4 cohorts.
COHORT 1:
INDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA + VENETOCLAX: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, venetoclax PO or NG QD on days 22-35, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
COHORT 2:
INDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14 and 29-42, cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
COHORT 3:
INDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14 and 29-42, cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA + VENETOCLAX: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, venetoclax PO or NG QD on days 22-35, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
COHORT 4:
INDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
ARM C:
INDUCTION: Patients receive daunorubicin IV over 1-15 minutes on days 1 and 2, cytarabine SC or IV over 1-30 minutes on days 1-14, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29, or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and methotrexate IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
CONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, methotrexate IT on days 8, 15, and 22, vincristine IV on days 15, 22, 43, and 50, and calaspargase pegol IV over 1-2 hours on days 15 and 43. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to interim maintenance 1 the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
INTERIM MAINTENANCE 1: Patients receive vincristine IV on days 1, 15, 29, and 43, high dose methotrexate IV over 24 hours on days 1, 15, 29, and 43, mercaptopurine PO or NG on days 1-14, 15-28, 29-42, and 43-56, methotrexate IT on days 1 and 29, and leucovorin PO or NG or IV or levoleucovorin IV on days 3-4, 17-18, 31-32, and 45-46. At the end of interim maintenance 1 (day 63), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28, and methotrexate IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive methotrexate IT on days 1, 29, and 36, dexamethasone PO, NG, or IV BID on days 1-7 and 15-21, vincristine IV on days 1, 8, 15, 43, and 50, doxorubicin IV over 3-15 minutes on days 1, 8, and 15, calaspargase pegol IV over 1-2 hours on days 4 and 43, cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO or NG on days 29-42, and cytarabine SC or IV over 1-30 minutes on days 29-32 and 36-39. At the end of delayed intensification (day 63), all patients proceed directly to interim maintenance 2 the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
INTERIM MAINTENANCE 2: Patients receive vincristine IV on days 1, 11, 21, 31, and 41, methotrexate IV push over 2-5 minutes or IV over 10-15 minutes on days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and calaspargase pegol IV over 1-2 hours on days 2 and 23. At the end of interim maintenance 2 (day 56), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MAINTENANCE: Patients receive methotrexate IT on day 1 of cycles 1-3, vincristine IV on day 1 of each cycle, prednisone or prednisolone PO or NG BID or methylprednisolone IV BID on days 1-5 of each cycle, mercaptopurine PO or NG on days 1-84 of each cycle, and methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of interim maintenance 1 in the absence of disease progression or unacceptable toxicity.
All patients undergo bone marrow aspiration, collection of blood samples and echocardiography (ECHO) or multigated acquisition scan (MUGA) throughout the trial. Patients may undergo computed tomography (CT), magnetic resonance imaging (MRI), fludeoxyglucose-positron emission tomography (FDG-PET), and/or lumbar puncture if clinically indicated.
After completion of study treatment, patients are followed up for up to 3 years.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
San Juan, Porto Rico, 00926
- Reclutamento
- University Pediatric Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 787-474-0333
-
Investigatore principale:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Reclutamento
- Children's Hospital of Alabama
-
Contatto:
- Site Public Contact
- Numero di telefono: 205-638-9285
- Email: oncologyresearch@peds.uab.edu
-
Investigatore principale:
- Matthew A. Kutny
-
-
Alaska
-
Anchorage, Alaska, Stati Uniti, 99508
- Reclutamento
- Providence Alaska Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 907-212-6871
- Email: AKPAMC.OncologyResearchSupport@providence.org
-
Investigatore principale:
- Brenda J. Wittman
-
-
Arizona
-
Mesa, Arizona, Stati Uniti, 85202
- Reclutamento
- Banner Children's at Desert
-
Contatto:
- Site Public Contact
- Numero di telefono: 480-412-3100
-
Investigatore principale:
- Joseph C. Torkildson
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72202-3591
- Reclutamento
- Arkansas Children's Hospital
-
Investigatore principale:
- Michael W. Bishop
-
Contatto:
- Site Public Contact
- Numero di telefono: 501-364-7373
-
-
California
-
Loma Linda, California, Stati Uniti, 92354
- Reclutamento
- Loma Linda University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 909-558-4050
-
Investigatore principale:
- Albert Kheradpour
-
Long Beach, California, Stati Uniti, 90806
- Reclutamento
- Miller Children's and Women's Hospital Long Beach
-
Contatto:
- Site Public Contact
- Numero di telefono: 562-933-5600
-
Investigatore principale:
- Jacqueline N. Casillas
-
Oakland, California, Stati Uniti, 94611
- Reclutamento
- Kaiser Permanente-Oakland
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Aarati V. Rao
-
Oakland, California, Stati Uniti, 94609
- Reclutamento
- UCSF Benioff Children's Hospital Oakland
-
Investigatore principale:
- Anya Levinson
-
Contatto:
- Site Public Contact
- Numero di telefono: 510-428-3264
- Email: PedOncRschOAK@ucsf.edu
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- Children's Hospital of Orange County
-
Contatto:
- Site Public Contact
- Numero di telefono: 714-509-8646
- Email: oncresearch@choc.org
-
Investigatore principale:
- Elyssa M. Rubin
-
Sacramento, California, Stati Uniti, 95817
- Reclutamento
- University of California Davis Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 916-734-3089
-
Investigatore principale:
- Marcio H. Malogolowkin
-
San Francisco, California, Stati Uniti, 94158
- Reclutamento
- UCSF Medical Center-Mission Bay
-
Investigatore principale:
- Anya Levinson
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-827-3222
- Email: cancertrials@ucsf.edu
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- Children's Hospital Colorado
-
Investigatore principale:
- Kelly E. Faulk
-
Contatto:
- Site Public Contact
- Numero di telefono: 303-764-5056
- Email: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06106
- Reclutamento
- Connecticut Children's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 860-545-9981
-
Investigatore principale:
- Michael S. Isakoff
-
New Haven, Connecticut, Stati Uniti, 06520
- Reclutamento
- Yale University
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Investigatore principale:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, Stati Uniti, 19803
- Reclutamento
- Alfred I duPont Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Emi H. Caywood
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Reclutamento
- Children's National Medical Center
-
Investigatore principale:
- Jeffrey S. Dome
-
Contatto:
- Site Public Contact
- Numero di telefono: 202-476-2800
- Email: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32610
- Reclutamento
- UF Health Cancer Institute - Gainesville
-
Investigatore principale:
- Brian Stover
-
Contatto:
- Site Public Contact
- Numero di telefono: 352-273-8010
-
Hollywood, Florida, Stati Uniti, 33021
- Reclutamento
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 954-265-1847
- Email: OHR@mhs.net
-
Investigatore principale:
- Iftikhar Hanif
-
Jacksonville, Florida, Stati Uniti, 32207
- Reclutamento
- Nemours Children's Clinic-Jacksonville
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Emi H. Caywood
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 305-243-2647
-
Investigatore principale:
- Julio C. Barredo
-
Orlando, Florida, Stati Uniti, 32806
- Reclutamento
- Arnold Palmer Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 321-841-5357
- Email: Jennifer.spinelli@orlandohealth.com
-
Investigatore principale:
- Zhongbo Hu
-
Orlando, Florida, Stati Uniti, 32827
- Reclutamento
- Nemours Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Emi H. Caywood
-
Orlando, Florida, Stati Uniti, 32803
- Reclutamento
- AdventHealth Orlando
-
Contatto:
- Site Public Contact
- Numero di telefono: 407-303-2090
- Email: FH.Cancer.Research@flhosp.org
-
Investigatore principale:
- Fouad M. Hajjar
-
Pensacola, Florida, Stati Uniti, 32504
- Reclutamento
- Nemours Children's Clinic - Pensacola
-
Contatto:
- Site Public Contact
- Email: helpdesk@childrensoncologygroup.org
-
Investigatore principale:
- Jeffrey H. Schwartz
-
St. Petersburg, Florida, Stati Uniti, 33701
- Reclutamento
- Johns Hopkins All Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 727-767-4784
- Email: Ashley.Repp@jhmi.edu
-
Investigatore principale:
- Jennifer B. Dean
-
Tampa, Florida, Stati Uniti, 33607
- Reclutamento
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Contatto:
- Site Public Contact
- Numero di telefono: 813-357-0849
- Email: jennifer.manns@baycare.org
-
Investigatore principale:
- Don E. Eslin
-
West Palm Beach, Florida, Stati Uniti, 33407
- Reclutamento
- Saint Mary's Medical Center
-
Investigatore principale:
- Matthew D. Ramirez
-
Contatto:
- Site Public Contact
- Numero di telefono: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- Reclutamento
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Investigatore principale:
- Melinda G. Pauly
-
Contatto:
- Site Public Contact
- Numero di telefono: 404-785-0232
- Email: Olivia.Floyd@choa.org
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96826
- Reclutamento
- Kapiolani Medical Center for Women and Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 808-983-6090
-
Investigatore principale:
- Wade T. Kyono
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83712
- Reclutamento
- Saint Luke's Cancer Institute - Boise
-
Investigatore principale:
- Martha M. Pacheco
-
Contatto:
- Site Public Contact
- Numero di telefono: 208-381-2774
- Email: eslinget@slhs.org
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Lurie Children's Hospital-Chicago
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-880-4562
-
Investigatore principale:
- Sara Zarnegar-Lumley
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- University of Chicago Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-702-8222
- Email: cancerclinicaltrials@bsd.uchicago.edu
-
Investigatore principale:
- Gabrielle Lapping-Carr
-
Oak Lawn, Illinois, Stati Uniti, 60453
- Reclutamento
- Advocate Children's Hospital-Oak Lawn
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-723-7570
-
Investigatore principale:
- Rebecca E. McFall
-
Park Ridge, Illinois, Stati Uniti, 60068
- Reclutamento
- Advocate Children's Hospital-Park Ridge
-
Contatto:
- Site Public Contact
- Email: helpdesk@childrensoncologygroup.org
-
Investigatore principale:
- Rebecca E. McFall
-
Peoria, Illinois, Stati Uniti, 61637
- Reclutamento
- OSF Children's Hospital of Illinois
-
Investigatore principale:
- Prerna Kumar
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-624-4945
- Email: ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield, Illinois, Stati Uniti, 62702
- Reclutamento
- Southern Illinois University School of Medicine
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-545-7929
-
Investigatore principale:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Reclutamento
- Riley Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-248-1199
-
Investigatore principale:
- Amanda Saraf
-
Indianapolis, Indiana, Stati Uniti, 46260
- Reclutamento
- Ascension Saint Vincent Indianapolis Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 317-338-2194
- Email: research@stvincent.org
-
Investigatore principale:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Stati Uniti, 50309
- Reclutamento
- Blank Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-8912
- Email: samantha.mallory@unitypoint.org
-
Investigatore principale:
- Samantha L. Mallory
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- Reclutamento
- University of Kentucky/Markey Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 859-257-3379
-
Investigatore principale:
- James T. Badgett
-
Louisville, Kentucky, Stati Uniti, 40202
- Reclutamento
- Norton Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 502-629-5500
- Email: CancerResource@nortonhealthcare.org
-
Investigatore principale:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70118
- Reclutamento
- Children's Hospital New Orleans
-
Investigatore principale:
- Maria C. Velez-Yanguas
-
Contatto:
- Site Public Contact
- Numero di telefono: 504-894-5377
-
New Orleans, Louisiana, Stati Uniti, 70121
- Reclutamento
- Ochsner Medical Center Jefferson
-
Contatto:
- Site Public Contact
- Numero di telefono: 504-842-8084
- Email: Elisemarie.curry@ochsner.org
-
Investigatore principale:
- Craig Lotterman
-
-
Maine
-
Scarborough, Maine, Stati Uniti, 04074
- Reclutamento
- Maine Children's Cancer Program
-
Investigatore principale:
- Sei-Gyung K. Sze
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Investigatore principale:
- Stacy L. Cooper
-
Contatto:
- Site Public Contact
- Numero di telefono: 410-955-8804
- Email: jhcccro@jhmi.edu
-
Baltimore, Maryland, Stati Uniti, 21215
- Reclutamento
- Sinai Hospital of Baltimore
-
Investigatore principale:
- Jason M. Fixler
-
Contatto:
- Site Public Contact
- Numero di telefono: 410-601-9083
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Dana-Farber Cancer Institute
-
Investigatore principale:
- Melissa A. Burns
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-442-3324
-
Worcester, Massachusetts, Stati Uniti, 01655
- Reclutamento
- UMass Memorial Medical Center - University Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 508-856-3216
- Email: cancer.research@umassmed.edu
-
Investigatore principale:
- Stefanie R. Lowas
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- C S Mott Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-865-1125
-
Investigatore principale:
- Joshua W. Goldman
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Reclutamento
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Investigatore principale:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Reclutamento
- Bronson Methodist Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Investigatore principale:
- Kathleen Y. Butler
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Reclutamento
- University of Minnesota/Masonic Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 612-624-2620
-
Investigatore principale:
- Peter M. Gordon
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- Reclutamento
- University of Mississippi Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 601-815-6700
-
Investigatore principale:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64108
- Reclutamento
- Children's Mercy Hospitals and Clinics
-
Investigatore principale:
- Keith J. August
-
Contatto:
- Site Public Contact
- Numero di telefono: 816-302-6808
- Email: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University School of Medicine
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Investigatore principale:
- Laura G. Schuettpelz
-
St Louis, Missouri, Stati Uniti, 63141
- Reclutamento
- Mercy Hospital Saint Louis
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-251-7066
-
Investigatore principale:
- Robin D. Hanson
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Reclutamento
- Children's Hospital and Medical Center of Omaha
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-955-3949
-
Investigatore principale:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89135
- Reclutamento
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Contatto:
- Site Public Contact
- Numero di telefono: 702-384-0013
- Email: research@sncrf.org
-
Investigatore principale:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Reclutamento
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Investigatore principale:
- Angela Ricci
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-639-6918
- Email: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Reclutamento
- Hackensack University Medical Center
-
Investigatore principale:
- Jing Chen
-
Contatto:
- Site Public Contact
- Numero di telefono: 551-996-2897
-
Morristown, New Jersey, Stati Uniti, 07960
- Reclutamento
- Morristown Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-971-5900
-
Investigatore principale:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Reclutamento
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Investigatore principale:
- Marissa Botwinick
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-235-8675
-
Paterson, New Jersey, Stati Uniti, 07503
- Reclutamento
- Saint Joseph's Regional Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-754-2207
- Email: HallL@sjhmc.org
-
Investigatore principale:
- Alissa Kahn
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Reclutamento
- Albany Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 518-262-5513
-
Investigatore principale:
- Lauren R. Weintraub
-
Buffalo, New York, Stati Uniti, 14263
- Reclutamento
- Roswell Park Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-767-9355
- Email: askroswell@roswellpark.org
-
Investigatore principale:
- Lisa Niswander
-
New Hyde Park, New York, Stati Uniti, 11040
- Reclutamento
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Contatto:
- Site Public Contact
- Numero di telefono: 718-470-3460
-
Investigatore principale:
- Julie I. Krystal
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-639-7592
-
Investigatore principale:
- Kavitha Ramaswamy
-
New York, New York, Stati Uniti, 10016
- Reclutamento
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Investigatore principale:
- Elizabeth A. Raetz
-
Contatto:
- Site Public Contact
- Email: CancerTrials@nyulangone.org
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- NYP/Weill Cornell Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-746-1848
-
Investigatore principale:
- Jaclyn Rosenzweig
-
Rochester, New York, Stati Uniti, 14642
- Reclutamento
- University of Rochester
-
Contatto:
- Site Public Contact
- Numero di telefono: 585-275-5830
-
Investigatore principale:
- Carol Fries Simpson
-
Syracuse, New York, Stati Uniti, 13210
- Reclutamento
- State University of New York Upstate Medical University
-
Contatto:
- Site Public Contact
- Numero di telefono: 315-464-5476
-
Investigatore principale:
- Melanie A. Comito
-
The Bronx, New York, Stati Uniti, 10467
- Reclutamento
- Montefiore Medical Center - Moses Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 718-379-6866
- Email: eskwak@montefiore.org
-
Investigatore principale:
- Alice Lee
-
Valhalla, New York, Stati Uniti, 10595
- Reclutamento
- New York Medical College
-
Contatto:
- Site Public Contact
- Numero di telefono: 914-594-3794
-
Investigatore principale:
- Andrew J. Bellantoni
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- Reclutamento
- UNC Lineberger Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-668-0683
- Email: cancerclinicaltrials@med.unc.edu
-
Investigatore principale:
- Thomas B. Alexander
-
Charlotte, North Carolina, Stati Uniti, 28203
- Reclutamento
- Carolinas Medical Center/Levine Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-804-9376
-
Investigatore principale:
- Joel A. Kaplan
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke University Medical Center
-
Investigatore principale:
- Jessica M. Sun
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-275-3853
-
Greenville, North Carolina, Stati Uniti, 27834
- Reclutamento
- East Carolina University
-
Contatto:
- Site Public Contact
- Numero di telefono: 252-744-1015
- Email: eubankss@ecu.edu
-
Investigatore principale:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Reclutamento
- Wake Forest University Health Sciences
-
Contatto:
- Site Public Contact
- Numero di telefono: 336-713-6771
-
Investigatore principale:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Broadway Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Investigatore principale:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Stati Uniti, 44308
- Reclutamento
- Children's Hospital Medical Center of Akron
-
Contatto:
- Site Public Contact
- Numero di telefono: 330-543-3193
-
Investigatore principale:
- Lauren R. Draper
-
Cincinnati, Ohio, Stati Uniti, 45229
- Reclutamento
- Cincinnati Children's Hospital Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 513-636-2799
- Email: cancer@cchmc.org
-
Investigatore principale:
- Erin H. Breese
-
Cleveland, Ohio, Stati Uniti, 44106
- Reclutamento
- Rainbow Babies and Childrens Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 216-844-5437
-
Investigatore principale:
- Duncan S. Stearns
-
Dayton, Ohio, Stati Uniti, 45404
- Reclutamento
- Dayton Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-228-4055
-
Investigatore principale:
- Jordan M. Wright
-
Toledo, Ohio, Stati Uniti, 43606
- Reclutamento
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 419-824-1842
- Email: PCIOncResearch@promedica.org
-
Investigatore principale:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma Health Sciences Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Investigatore principale:
- Rene Y. McNall-Knapp
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Reclutamento
- Lehigh Valley Hospital-Cedar Crest
-
Contatto:
- Site Public Contact
- Numero di telefono: 610-402-9543
- Email: Morgan_M.Horton@lvhn.org
-
Investigatore principale:
- Jacob A. Troutman
-
Danville, Pennsylvania, Stati Uniti, 17822
- Reclutamento
- Geisinger Medical Center
-
Investigatore principale:
- Jagadeesh Ramdas
-
Contatto:
- Site Public Contact
- Numero di telefono: 570-271-5251
- Email: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Reclutamento
- Penn State Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 717-531-6012
-
Investigatore principale:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Children's Hospital of Philadelphia
-
Contatto:
- Site Public Contact
- Numero di telefono: 267-425-5544
- Email: CancerTrials@email.chop.edu
-
Investigatore principale:
- Kathrin M. Bernt
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Reclutamento
- Children's Hospital of Pittsburgh of UPMC
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-692-8570
- Email: jean.tersak@chp.edu
-
Investigatore principale:
- Jenny Ruiz
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Reclutamento
- Rhode Island Hospital
-
Investigatore principale:
- Bradley DeNardo
-
Contatto:
- Site Public Contact
- Numero di telefono: 401-444-1488
-
-
South Carolina
-
Columbia, South Carolina, Stati Uniti, 29203
- Reclutamento
- Prisma Health Richland Hospital
-
Investigatore principale:
- Stuart L. Cramer
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- BI-LO Charities Children's Cancer Center
-
Investigatore principale:
- Aniket Saha
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Reclutamento
- Sanford USD Medical Center - Sioux Falls
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
- Email: OncologyClinicalTrialsSF@SanfordHealth.org
-
Investigatore principale:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37916
- Reclutamento
- East Tennessee Childrens Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 865-541-8266
-
Investigatore principale:
- Susan E. Spiller
-
Memphis, Tennessee, Stati Uniti, 38105
- Reclutamento
- Saint Jude Children's Research Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-226-4343
- Email: referralinfo@stjude.org
-
Investigatore principale:
- Matthew Rees
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University/Ingram Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-811-8480
-
Investigatore principale:
- Brianna N. Smith
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- The Children's Hospital at TriStar Centennial
-
Contatto:
- Site Public Contact
- Numero di telefono: 615-342-1919
-
Investigatore principale:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Stati Uniti, 78723
- Reclutamento
- Dell Children's Medical Center of Central Texas
-
Contatto:
- Site Public Contact
- Numero di telefono: 512-628-1902
- Email: TXAUS-DL-SFCHemonc.research@ascension.org
-
Investigatore principale:
- Shannon M. Cohn
-
Corpus Christi, Texas, Stati Uniti, 78411
- Reclutamento
- Driscoll Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 361-694-5311
- Email: Crystal.DeLosSantos@dchstx.org
-
Investigatore principale:
- Nkechi I. Mba
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contatto:
- Site Public Contact
- Numero di telefono: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Investigatore principale:
- Caroline Smith
-
Dallas, Texas, Stati Uniti, 75230
- Reclutamento
- Medical City Dallas Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 972-566-5588
-
Investigatore principale:
- Maurizio L. Ghisoli
-
El Paso, Texas, Stati Uniti, 79905
- Reclutamento
- El Paso Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 915-298-5444
- Email: ranjan.bista@ttuhsc.edu
-
Investigatore principale:
- Benjamin Carcamo
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- Cook Children's Medical Center
-
Investigatore principale:
- Holly Pacenta
-
Contatto:
- Site Public Contact
- Numero di telefono: 682-885-2103
- Email: CookChildrensResearch@cookchildrens.org
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Investigatore principale:
- Joanna S. Yi
-
Contatto:
- Site Public Contact
- Numero di telefono: 713-798-1354
- Email: burton@bcm.edu
-
San Antonio, Texas, Stati Uniti, 78207
- Reclutamento
- Children's Hospital of San Antonio
-
Contatto:
- Site Public Contact
- Numero di telefono: 210-704-2894
- Email: bridget.medina@christushealth.org
-
Investigatore principale:
- Julie Voeller
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Methodist Children's Hospital of South Texas
-
Contatto:
- Site Public Contact
- Numero di telefono: 210-575-6240
- Email: Vinod.GidvaniDiaz@hcahealthcare.com
-
Investigatore principale:
- Jose M. Esquilin
-
Temple, Texas, Stati Uniti, 76508
- Reclutamento
- Scott and White Memorial Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 254-724-5407
-
Investigatore principale:
- Nicholas W. McGregor
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22908
- Reclutamento
- University of Virginia Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 434-243-6303
- Email: uvacancertrials@hscmail.mcc.virginia.edu
-
Investigatore principale:
- Brian C. Belyea
-
Norfolk, Virginia, Stati Uniti, 23507
- Reclutamento
- Children's Hospital of The King's Daughters
-
Contatto:
- Site Public Contact
- Numero di telefono: 757-668-7243
- Email: CCBDCresearch@chkd.org
-
Investigatore principale:
- Melissa S. Mark
-
Richmond, Virginia, Stati Uniti, 23298
- Reclutamento
- VCU Massey Comprehensive Cancer Center
-
Investigatore principale:
- Jordyn R. Griffin
-
Contatto:
- Site Public Contact
- Numero di telefono: 804-628-6430
- Email: CTOclinops@vcu.edu
-
Roanoke, Virginia, Stati Uniti, 24014
- Reclutamento
- Carilion Children's
-
Contatto:
- Site Public Contact
- Numero di telefono: 540-266-6238
- Email: wpmccarty@carilionclinic.org
-
Investigatore principale:
- Erwood G. Edwards
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Reclutamento
- Seattle Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-987-2000
-
Investigatore principale:
- Sarah E. Leary
-
Spokane, Washington, Stati Uniti, 99204
- Reclutamento
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-228-6618
- Email: HopeBeginsHere@providence.org
-
Investigatore principale:
- Judy L. Felgenhauer
-
-
Wisconsin
-
Green Bay, Wisconsin, Stati Uniti, 54301
- Reclutamento
- Saint Vincent Hospital Cancer Center Green Bay
-
Investigatore principale:
- Catherine A. Long
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-433-8889
- Email: WI_research_admin@hshs.org
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Children's Hospital of Wisconsin
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-955-4727
- Email: MACCCTO@mcw.edu
-
Investigatore principale:
- Zachary Graff
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
All patients must be enrolled on APEC14B1 and consented to eligibility screening (part A) prior to treatment and enrollment on AALL2321
-
Infants (aged 365 days or less) on the date of diagnosis are eligible; infants must be > 36 weeks gestational age (cumulative prenatal and postnatal age must be > 36 weeks) at the time of enrollment
-
Patients must have newly diagnosed B-acute lymphoblastic leukemia (B-ALL, 2017 World Health Organization [WHO] classification), also termed B-precursor ALL, or acute leukemia of ambiguous lineage (ALAL), which includes mixed phenotype acute leukemia. For patients with ALAL, the immunophenotype of the leukemia must comprise at least 50% B lineage
- Diagnostic immunophenotype: Leukemia cells must express CD19
Exclusion Criteria:
-
Patients with Down Syndrome
-
Patients with secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy
-
Patients must not have received any cytotoxic chemotherapy for either the current diagnosis of infant ALL or for any cancer diagnosis prior to the initiation of protocol therapy, with the exception of:
-
Steroid pretreatment:
- PredniSONE, prednisoLONE, or methylPREDNISolone for ≤ 72 hours (3 days) in the 7 days prior to enrollment. The dose of predniSONE, prednisoLONE or methylPREDNISolone does not affect eligibility
- Inhaled and topical steroids are not considered pretreatment
- Note: Pretreatment with dexamethasone in the 28 days prior to initiation of protocol therapy is not allowed with the exception of a single dose of dexamethasone used during or within 6 hours prior to or after sedation to prevent or treat airway edema. However, prior exposure to ANY steroids that occurred > 28 days before enrollment does not affect eligibility
-
Intrathecal cytarabine or methotrexate:
- An intrathecal dose of cytarabine or methotrexate in the 7 days prior to enrollment does not affect eligibility
- Note: The preference is to defer the diagnostic lumbar puncture with intrathecal chemotherapy to day 1 of induction to allow for cytoreduction of circulating blasts and decrease the potential for central nervous system (CNS) contamination due to a traumatic tap. If done prior to day 1 of induction, these results will be used to determine CNS status
-
Hydroxyurea:
- Pretreatment with ≤ 72 hours (3 days) of hydroxyurea in the 7 days prior to enrollment does not affect eligibility
-
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA) and National Cancer Institute (NCI) requirements for human studies must be met
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Arm A
See Detailed Description for Arm A. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo lumbar puncture
Altri nomi:
Undergo collection of blood samples
Altri nomi:
Given IV
Altri nomi:
Given IT
Altri nomi:
Given recombinant crisantaspase IM or crisantaspase IM or IV
Altri nomi:
Given IT or IV
Altri nomi:
Given PO or NG or IV
Altri nomi:
Undergo FDG-PET
Altri nomi:
Given PO or NG or IV
Altri nomi:
Given IV
Altri nomi:
Given PO or NG
Altri nomi:
Given IT or IV or PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
|
|
Sperimentale: Arm B, Cohort 1
See Detailed Description for Arm B, Cohort 1. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo lumbar puncture
Altri nomi:
Undergo collection of blood samples
Altri nomi:
Given IV
Altri nomi:
Given IT
Altri nomi:
Given recombinant crisantaspase IM or crisantaspase IM or IV
Altri nomi:
Given IT or IV
Altri nomi:
Given PO or NG or IV
Altri nomi:
Undergo FDG-PET
Altri nomi:
Given PO or NG or IV
Altri nomi:
Given IV
Altri nomi:
Given PO or NG
Altri nomi:
Given IT or IV or PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
|
|
Sperimentale: Arm B, Cohort 2
See Detailed Description for Arm B, Cohort 2. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo lumbar puncture
Altri nomi:
Undergo collection of blood samples
Altri nomi:
Given IV
Altri nomi:
Given IT
Altri nomi:
Given recombinant crisantaspase IM or crisantaspase IM or IV
Altri nomi:
Given IT or IV
Altri nomi:
Given PO or NG or IV
Altri nomi:
Undergo FDG-PET
Altri nomi:
Given PO or NG or IV
Altri nomi:
Given IV
Altri nomi:
Given PO or NG
Altri nomi:
Given IT or IV or PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
|
|
Sperimentale: Arm B, Cohort 3
See Detailed Description for Arm B, Cohort 3. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo lumbar puncture
Altri nomi:
Undergo collection of blood samples
Altri nomi:
Given IV
Altri nomi:
Given IT
Altri nomi:
Given recombinant crisantaspase IM or crisantaspase IM or IV
Altri nomi:
Given IT or IV
Altri nomi:
Given PO or NG or IV
Altri nomi:
Undergo FDG-PET
Altri nomi:
Given PO or NG or IV
Altri nomi:
Given IV
Altri nomi:
Given PO or NG
Altri nomi:
Given IT or IV or PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
|
|
Sperimentale: Arm B, Cohort 4
See Detailed Description for Arm B, Cohort 4. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo lumbar puncture
Altri nomi:
Undergo collection of blood samples
Altri nomi:
Given IV
Altri nomi:
Given IT
Altri nomi:
Given recombinant crisantaspase IM or crisantaspase IM or IV
Altri nomi:
Given IT or IV
Altri nomi:
Given PO or NG or IV
Altri nomi:
Undergo FDG-PET
Altri nomi:
Given PO or NG or IV
Altri nomi:
Given IV
Altri nomi:
Given PO or NG
Altri nomi:
Given IT or IV or PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
|
|
Sperimentale: Arm C
See Detailed Description for Arm C. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo lumbar puncture
Altri nomi:
Given IV
Altri nomi:
Undergo collection of blood samples
Altri nomi:
Given IV
Altri nomi:
Given IT
Altri nomi:
Given IT or IV
Altri nomi:
Given PO or NG or IV
Altri nomi:
Undergo FDG-PET
Altri nomi:
Given PO or NG or IV
Altri nomi:
Given IV
Altri nomi:
Given PO or NG
Altri nomi:
Given IT or IV or PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
|
|
Sperimentale: Safety Phase Cohort
See Detailed Description for Safety Phase Cohort. (CLOSED TO ACCRUAL 06/03/2026) |
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Given IV
Altri nomi:
Undergo lumbar puncture
Altri nomi:
Undergo collection of blood samples
Altri nomi:
Given IV
Altri nomi:
Given IT
Altri nomi:
Given recombinant crisantaspase IM or crisantaspase IM or IV
Altri nomi:
Given IT or IV
Altri nomi:
Given PO or NG or IV
Altri nomi:
Undergo FDG-PET
Altri nomi:
Given PO or NG or IV
Altri nomi:
Given IV
Altri nomi:
Given PO or NG
Altri nomi:
Given IT or IV or PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
|
|
Sperimentale: Steroid Prephase(prednisone, prednisolone, methylprednisolone)
All patients receive prednisone or prednisolone PO or NG TID or methylprednisolone IV TID for 7 days prior to the start of induction therapy (on days 1-7). |
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo bone marrow aspiration Undergo lumbar puncture
Altri nomi:
Given IV
Altri nomi:
Undergo collection of blood samples
Altri nomi:
Undergo FDG-PET
Altri nomi:
Given PO or NG
Altri nomi:
Given PO or NG
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of dose-limiting toxicities (DLTs) (safety phase)
Lasso di tempo: For the duration of the induction + venetoclax cycle
|
For the safety phase, DLTs of the induction + venetoclax cycle of KMT2A-rearranged (R) patients will be assessed. |
For the duration of the induction + venetoclax cycle
|
|
Incidence of DLTs (expansion phase)
Lasso di tempo: During the induction, consolidation, and MARMA cycles of Arm B
|
For the expansion phase, DLTs of Arm B will be assessed and monitored for the cycles that contain venetoclax (induction, consolidation, and MARMA cycles of Arm B). |
During the induction, consolidation, and MARMA cycles of Arm B
|
|
Minimal residual disease (MRD)-negative remission rate
Lasso di tempo: At the end of induction
|
The end of induction MRD-negative remission rate will be compared between Arm A and Arm B. MRD negativity is defined as achievement of complete remission and MRD < 0.01% by flow cytometry. The MRD-negative remission rate at the end of induction between Arm A and Arm B will be compared using a one-sided Z test of proportions with Type I error of 0.15. |
At the end of induction
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
MRD-negative remission rate
Lasso di tempo: At the end of induction
|
MRD-negative remission rate at the end of induction and the standard error or 95% confidence interval will be estimated among infants with KMT2A-R acute lymphoblastic leukemia (ALL) treated with venetoclax at the RP2D. This analysis will include eligible KMT2A-R patients treated with venetoclax at the RP2D in the safety phase, as well as patients randomized to Arm B and treated with venetoclax in the expansion phase. MRD negativity is defined as < 0.01% by flow cytometry. |
At the end of induction
|
|
Event free survival (EFS) rates of infants with KMT2A-R ALL
Lasso di tempo: From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
The EFS rates from date of randomization of Arm B will be compared to Arm A. Comparison of EFS rates between Arm A and Arm B will be based on a one-sided logrank test with Type I error of 0.15. In addition, EFS rates will be estimated using the Kaplan-Meier method with Greenwood standard errors. Hazard ratios and confidence intervals will be estimated based on Cox regression models as appropriate. Cumulative incidence rates of each EFS event type (relapse, treatment failure, secondary malignant neoplasm and death) will also be estimated and presented with cumulative incidence curves and compared between arms as appropriate. |
From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
|
3-year EFS of infants with KMT2A-R ALL
Lasso di tempo: From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
For Arm A, the 3-year EFS rate (representing a plateau rate based on the shape of EFS curves of historical data in this patient population) from the date of randomization will be compared to the stable historical 3-year EFS rate of 35% observed in AALL0631 and other international trials. |
From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
|
Proportion of KMT2A-germline (G) patients in Arm C who are able to receive all treatment cycles before maintenance
Lasso di tempo: Up to interim maintenance 2
|
The feasibility of treating KMT2A-G patients with a high-risk ALL backbone and two cycles of blinatumomab (Arm C) will be assessed. Arm C treatment will be considered feasible for KMT2A-G patients if the proportion of KMT2A-G patients in Arm C who are able to receive all treatment cycles before maintenance (i.e., up to interim maintenance 2) is more than 76.8%. The proportion of patients receiving all cycles before Maintenance will be compared to 76.8% with a one-sample exact test of proportion with Type I error of 0.15. |
Up to interim maintenance 2
|
|
3-year EFS of infants with KMT2A-G ALL treated on Arm C
Lasso di tempo: From date of enrollment to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
The 3-year EFS rate from date of enrollment of KMT2A-G patients in Arm C will be estimated with the Kaplan-Meier method. |
From date of enrollment to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
|
Pharmacokinetics (PK) of venetoclax in infants
Lasso di tempo: On days 7, 10, and 14 of induction
|
PK samples will be collected from patients enrolled in the safety phase of the study as well as from patients randomized to Arm B in the expansion phase who consent to participate, to determine the major secondary objective of characterizing the PK of venetoclax in infants. PK samples will be evaluated in batches and standard nonlinear mixed effect modeling will be used for model building and refinement of time-concentration data. After model refinement, a non-parametric bootstrap analysis will be performed reporting the 95% confidence intervals for each PK parameter. |
On days 7, 10, and 14 of induction
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
3-year EFS of infants with KMT2A-R ALL treated on Arm B
Lasso di tempo: From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
Arm B, the 3-year EFS rate from date of randomization will be estimated, and will be compared to Arm A as described in the secondary objective, and to historical 3-year EFS. Comparison to historical rate will be based on a one-sample test of proportion with one-sided Type I error of 0.15. |
From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
|
Use of high-throughput sequencing (HTS) for MRD detection in infant ALL compared to centralized flow cytometry
Lasso di tempo: Up to 3 years
|
Pre-treatment HTS clonality and HTS MRD tracking results will be collected and compared to the required centralized flow cytometry-based MRD data to evaluate the feasibility and prognostic utility of HTS MRD evaluation in the infant ALL population. |
Up to 3 years
|
|
PK of calaspargase pegol in infants with ALL
Lasso di tempo: At completion of the trial, up to 3 years
|
PK of calaspargase pegol will be analyzed by monitoring asparaginase activity levels. Once a PK model is developed for calaspargase pegol, standard regression analysis will be used to describe the relationship between drug exposure and asparaginase activity. Additionally, asparaginase-associated toxicities will be described for the entire study population and correlated with activity levels when possible. The result of this analysis will be an estimation of potential optimal exposure expected to yield the maximum efficacy while limiting toxicity. These analyses will be exploratory and descriptive. |
At completion of the trial, up to 3 years
|
|
Incidence of CD19-negative relapse and myeloid switch relapse with protocol therapy
Lasso di tempo: At the time of relapse, up to 3 years
|
For patients who experience relapse, will collect information regarding the immunophenotype of the leukemic blasts at time of relapse. Will report on the rate of CD19 negative relapse as well as myeloid switch relapse for all patients enrolled on study. This analysis will be exploratory and descriptive. |
At the time of relapse, up to 3 years
|
|
Impact of venetoclax in combination with chemotherapy on T-cell subsets and function
Lasso di tempo: Prior to and following the first course of venetoclax
|
BCL-2 inhibition is reported to alter T-cell subsets, including increased activation, enhanced cytotoxicity against leukemia cells and heightened resistance to cell death. Peripheral blood and bone marrow samples will be collected prior to and following the first course of venetoclax to evaluate effects on T-cell subsets and function following venetoclax exposure. |
Prior to and following the first course of venetoclax
|
|
Feasibility of T-cell collection and success of T-cell manufacturing for infants with KMT2A-R ALL who receive chimeric antigen receptor (CAR) T-cell therapy
Lasso di tempo: After coming off protocol therapy
|
For patients that undergo T-cell collection, will collect data regarding the feasibility of T-cell collection in the context of protocol therapy. Additionally, for patients who proceed with CAR T-cell therapy after coming off protocol therapy, will collect data regarding the success of T-cell manufacturing, infusion and response to therapy in this young population, as the success of this subsequent therapy may be heavily impacted by the effect of protocol therapy on T-cell function. These analyses will be exploratory and descriptive. |
After coming off protocol therapy
|
|
Predictors of response and resistance to venetoclax and overall protocol therapy
Lasso di tempo: Before and after venetoclax exposure, up to 3 years
|
Will study the inter- and intra- patient variability in the expression of apoptotic proteins (e.g., BCL-2, MCL-1, BCL-XL) and apoptotic priming at diagnosis and identify changes that occur during induction therapy in relationship to venetoclax exposure. Will then determine whether the state of BCL-2 specific apoptotic priming correlates with outcome. Will also integrate genomic and molecular features (such as developmental state, signaling, epigenomic, transcriptomic, proteomic and metabolomic states) before and after venetoclax exposure, for those assays where this type of analysis is feasible, to determine biomarkers of response and resistance to therapy for infants with ALL. |
Before and after venetoclax exposure, up to 3 years
|
|
Impact of subsequent anti-cancer therapy on overall survival
Lasso di tempo: After coming off protocol therapy
|
For all patients who remain in study follow-up after coming off protocol therapy, data will be collected regarding subsequent cancer directed therapies received as well as relapse and survival status in order to evaluate the impact of subsequent cancer directed therapy on the overall survival of patients enrolled on this study. These analyses will be exploratory and descriptive. |
After coming off protocol therapy
|
|
Overall survival (OS) rates
Lasso di tempo: From randomization to death due to any cause, up to 3 years
|
Will compare OS rates of infants by arms and to historical OS rates. The OS rates from the date of randomization of patients with KMT2A-R ALL will be compared between Arm A and Arm B. Comparison of OS rates between Arm A and Arm B will be based on a one-sided logrank test with Type I error of 0.15. In addition, OS rates of KMT2A-R patients in Arm A and Arm B will be compared to historical rates observed in similar patients in completed studies such as AALL0631 or AALL15P1. In addition, OS from enrollment of KMT2A-G patients will be compared to historical rates. OS rates will be estimated using the Kaplan-Meier method with Greenwood standard errors. Hazard ratios and confidence intervals will be estimated based on Cox regression models as appropriate. These analyses will be largely exploratory. |
From randomization to death due to any cause, up to 3 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Erin H Breese, Children's Oncology Group
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Malattie del sistema immunitario
- Infezioni
- Malattie virali
- Neoplasie per tipo istologico
- Malattie ematologiche
- Infezioni da virus del DNA
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Linfoma, cellule B
- Linfoma
- Leucemia, linfoide
- Leucemia
- Infezioni da virus di Epstein-Barr
- Infezioni da Herpesviridae
- Infezioni da virus tumorali
- Malattie emiche e linfatiche
- Linfoma di Burkitt
- Leucemia, bifenotipica, acuta
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Tecniche investigative
- Terapie
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Forature
- Procedure chirurgiche, operative
- Acidi nucleici, nucleotidi e nucleosidi
- Biopsia
- Idrocarburi
- Idrocarburi, ciclici
- Carboidrati
- Alcaloidi
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Glicosidi
- Idrolasi
- Enzimi
- Enzimi e coenzimi
- Indoli
- Purine
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Steroidi, fluorurati
- Derivati di benzene
- Tecniche di chimica, analitiche
- Acidi solfonici
- Acidi zolfo
- Analisi dello spettro
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Nucleosidi
- Formyltetraidrofolates
- Tetraidrofolati
- Acido folico
- Pterins
- Pteridine
- Incintadienetrioli
- Incintadienediols
- Amidoidrolasi
- Vinca Alkaloids
- Alcaloidi di triptamina di secologia
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Arabinonucleosidi
- Aminopterino
- Antracicline
- Naftaceni
- Aminoglicosidi
- Coenzimi
- Gravideniones
- Incinta
- 11-idrossicosteroidi
- Idrossicorticosteroidi
- Ormoni della corteccia surrenale
- 17-idrossicosteroidi
- Tecniche diagnostiche, neurologiche
- Benzenesolfonati
- Arilsulfonati
- Acidi arilsolfonici
- Composti solfidrilici
- Desametasone
- Metotrexato
- Prednisone
- Prednisolone
- Ciclofosfamide
- Citarabina
- Leucovorina
- Levoleucovorin
- Doxorubicina
- Vincristina
- Metilprednisolone
- Daunorubicina
- Idrocortisone
- Asparaginasi
- Mercaptopurina
- Tioguanina
- Dobesilato di calcio
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Venetoclax
- Blinatumomab
- Puntura spinale
- desametasone 21-fosfato
- Deltacorne
- Prednylidene
- N, N-DICHCLOHEXYL-ISOBORNEOL-10-Sulfonamide
- Calaspargase Pegol
- azathiopurina
- Merphos
- auricolare
- desametasone acetato
- asparaginasi Erwinia chrysanthemi ricombinante
- Esifone
- Medrol Veriderm
Altri numeri di identificazione dello studio
- NCI-2024-01994
- U10CA180886 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2024-01994 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- AALL2321 (Altro identificatore: CTEP)
- AALL2321 (Altro identificatore: Children's Oncology Group)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .